Spyre Therapeutics Inc <SYRE.O>: Wedbush cuts target price to $123 from $130
SYRE•Related News
Figma Chief Accounting Officer Herb Tyler disposes of 1,840 common shares worth $49,937.6
FIG•
Aimei Health risks Nasdaq delisting after market value falls below $50 million threshold
AFJK•
Target Hospitality jumps after annual revenue forecast raise
TH•
Canada's Reklaim Q2 revenue more than doubles
XLK•
Albemarle Chief Accounting Officer Max Hood files initial beneficial ownership statement
ALB•